Compare Google Inc (GOOG) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Novavax Inc — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: Google Inc is far larger — about 2329.7× Novavax Inc's market cap, and Google Inc pays a 0.26% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Novavax Inc for 59 Days on average.
| GOOG | NVAX | |
|---|---|---|
Market Cap | $4.24T | $1.82B |
Volume | 13,937,902 | 6,198,505 |
Sector | Media | Health |
52-Week High | $399.06 | $12.56 |
52-Week Low | $237.49 | $6.22 |
Typical Hold Time | 137 Days | 59 Days |
Enterprise Value | $4.13T | $1.39B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.86, up 0.14% with strong technical momentum above key support levels. The stock shows robust fundamentals with revenue growth accelerating to $402.84B in 2025 and net income margins expanding to 32.8%. Recent earnings beats and a bullish analyst consensus at 87% buy ratings support the positive outlook, though elevated capital expenditures and regulatory scrutiny present near-term headwinds.
Alphabet's outlook remains favorable with AI-driven cloud growth and consistent earnings outperformance. The stock trades at a reasonable 17.3 P/E with 34% upside to the $435.24 consensus target. Key risks include massive AI infrastructure spending impacting cash flow and ongoing regulatory litigation. The technical setup suggests continued momentum toward resistance at $352-$354.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
